Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM1NTVQ)

Drug Name
Tadekinig alfa Drug Info
Indication
Disease Entry ICD 11 Status REF
XIAP deficiency 4A01.22 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DM1NTVQ

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-18 (IL18) TTRICUF IL18_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin-18 (IL18) DTT IL18 4.453 5.914 5.104 5.307
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease XIAP deficiency
ICD Disease Classification 4A01.22
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-18 (IL18) DTT IL18 1.46E-01 0.12 1.81
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03512314) Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of AB2 Bio.